Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kestra Medical TechnologiesKMTS +1.55%10 Equity-to-Asset is 0.72 as of Apr. 2026, which is 1100% above its 10-year median of 0.06. GuruFocus rates KMTS with a GF Score™ of 10/100. The stock has 3 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Kestra Medical Technologies ranks better than 68.27% on this metric.
The historical rank and industry rank for Kestra Medical Technologies's Equity-to-Asset or its related term are showing as below:
KMTS'
s Equity-to-Asset Range Over the Past 10 Years
Min: -4.56 Med: 0.06 Max: 0.76
Current: 0.76
During the past 5 years, the highest Equity to Asset Ratio of Kestra Medical Technologies was 0.76. The lowest was -4.56. And the median was 0.06.
KMTS's Equity-to-Asset is ranked better than 68.27% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.65
vs KMTS: 0.76
Kestra Medical Technologies (NAS:KMTS) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Kestra Medical Technologies Equity-to-Asset Related Terms
Kestra Medical Technologies Equity-to-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KMTS vs ATRC, STAA, BLFS: Equity-to-Asset Comparison
For the Medical Instruments & Supplies subindustry, Kestra Medical Technologies's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kestra Medical Technologies Equity-to-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Kestra Medical Technologies's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Kestra Medical Technologies's Equity-to-Asset falls into.
Kestra Medical Technologies Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Kestra Medical Technologies's Equity to Asset Ratio for the fiscal year that ended in Apr. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kestra Medical Technologies (KMTS) has a Equity-to-Asset of 0.72 as of Apr. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Kestra Medical Technologies and its competitors. This is 1100% above median its historical median of 0.06. According to the industry distribution chart, Kestra Medical Technologies ranks #271 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 31.7%.
Is Kestra Medical Technologies' Equity-to-Asset too high?
Kestra Medical Technologies' current Equity-to-Asset of 0.72 is 1100% above median its 10-year median of 0.06. The Medical Devices & Instruments industry median Equity-to-Asset is 0.65. Kestra Medical Technologies' value of 0.72 is 10.8% above this industry median. Based on the distribution chart, Kestra Medical Technologies ranks #271 out of 854 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Kestra Medical Technologies has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Kestra Medical Technologies' Equity-to-Asset compare to ATRC and STAA?
According to the Medical Devices & Instruments industry distribution chart, Kestra Medical Technologies ranks #271 out of 854 companies for Equity-to-Asset. This puts Kestra Medical Technologies in the upper half of its industry. The industry median Equity-to-Asset is 0.65. Kestra Medical Technologies' value of 0.72 is 10.8% above this benchmark. While the company's 10-year median is 0.06 vs. the industry median of 0.65, Kestra Medical Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Devices & Instruments company?
The median Equity-to-Asset among Medical Devices & Instruments companies is 0.65, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kestra Medical Technologies's current Equity-to-Asset of 0.72 is 10.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Kestra Medical Technologies and its competitors. For the Medical Devices & Instruments industry, the median Equity-to-Asset is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kestra Medical Technologies's current Equity-to-Asset is 0.72, which is 1100% above median its own 10-year median of 0.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kestra Medical Technologies stock overvalued right now?
Kestra Medical Technologies (KMTS) has a current Equity-to-Asset of 0.72. The current Equity-to-Asset is 0.72, which is 1100% above median its 10-year median of 0.06 and 10.8% above the Medical Devices & Instruments industry median of 0.65. Kestra Medical Technologies' overall GF Score™ is 10/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Kestra Medical Technologies (KMTS), the current Equity-to-Asset is 0.72 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
10GF Score
Get the complete analysis for KMTS
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KMTS has been successfully added to your 
